David Roman's questions to BOSTON SCIENTIFIC (BSX) leadership • Q3 2025
Question
David Roman of The Goldman Sachs Group, Inc. inquired about the growth dynamics and key drivers within Boston Scientific's business segments outside of the high-profile EP and WATCHMAN franchises, acknowledging the expected deceleration in EP growth. He sought insights into momentum in areas like neuromodulation, endoscopy, and peripheral interventions.
Answer
Chairman and CEO Mike Mahoney detailed strong performance across MedSurg (8% growth, robust endoscopy), anticipated acceleration in Urology for 2026 (Axonics focus), and significant gains in Neuromodulation (9% growth, bolstered by Nalu Medical acquisition and Relievant success). He also highlighted the transformation of ICTx (imaging, AGENT, upcoming IVL launches) and consistent double-digit growth in Interventional Oncology and Venous businesses, emphasizing continuous investment in R&D and tuck-in M&A.